# EDGAR Filing Document

**Accession Number:** 0000924020
**File Stem:** 0001021408-25-003584
**Filing Date:** 2025-8
**Character Count:** 8617
**Document Hash:** 2d9573894760e8a72e571c0f69a58d94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001021408-25-003584.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001021408-25-003584

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Johnson & Johnson Innovation - JJDC, Inc.
- **CENTRAL INDEX KEY:** 0000924020

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20073
- **FILM NUMBER:** 251259224

**BUSINESS ADDRESS:**
- **STREET 1:** 410 GEORGE STREET, SUITE 308
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08901
- **BUSINESS PHONE:** (732) 524-3218

**MAIL ADDRESS:**
- **STREET 1:** 410 GEORGE STREET, SUITE 308
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08901

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JOHNSON & JOHNSON DEVELOPMENT CORP ET AL
- **DATE OF NAME CHANGE:** 19940526

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0000924020

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Johnson  Johnson Innovation - JJDC, Inc.

**Address:** 410 George Street, New Brunswick, NJ 08901

**Telephone number:** 508-692-8812

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20073

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                  | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                             | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED    |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Adicet Bio, Inc.                | 007002108 | 6/11/2025      | To approve, on a non-binding advisory basis, the compensation of our named executive officers                                                                | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Altimmune Inc                   | 02155H200 | 9/26/2024      | An advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement                                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Arrowhead Pharmaceuticals, Inc. | 04280A100 | 3/12/2025      | To conduct an advisory (non-binding) vote to approve executive compensation                                                                                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Arrowhead Pharmaceuticals, Inc. | 04280A100 | 3/12/2025      | To conduct an advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation                                        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Fate Therapeutics, Inc.         | 31189P102 | 5/29/2025      | To conduct a non-binding advisory vote to approve the compensation of our named executive officers                                                           | SECTION 14A SAY-ON-PAY VOTES |        3379064 |                0 | FOR          |                                        0 | FOR                         |  |
| Fate Therapeutics, Inc.         | 31189P102 | 5/29/2025      | To conduct an advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation                                        | SECTION 14A SAY-ON-PAY VOTES |        3379064 |                0 | FOR          |                                        0 | FOR                         |  |
| Lyell Immunopharma Inc.         | 55083R104 | 5/15/2025      | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this Proxy Statement                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Marker Therapeutics, Inc.       | 57055L206 | 6/6/2025       | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Nano-X Imaging Ltd.             | M70700105 | 12/10/2024     | To approve the equity-based compensation terms of the non-executive directors who shall serve in such capacity immediately following the Meeting             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Procept BioRobotics Corporation | 74276L105 | 6/10/2025      | To approve, on a non-binding advisory basis, the compensation of our named executive officers                                                                | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Protagonist Therapeutics Inc    | 74366E102 | 6/20/2025      | To approve, on a non-binding, advisory basis, the compensaon of the Company's named executive officers                                                       | SECTION 14A SAY-ON-PAY VOTES |        2449183 |                0 | FOR          |                                        0 | FOR                         |  |
| Senseonics Holdings, Inc.       | 81727U105 | 5/21/2025      | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this Notice             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Standard Biotools, Inc.         | 34385P108 | 6/18/2025      | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement.                                     | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |
| Xencor, Inc.                    | 98401F105 | 6/12/2025      | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | DID NOT VOTE |                                        0 | NONE                        |  |

## N-PX: Signature Block

**Reporting Person:** Johnson  Johnson Innovation - JJDC, Inc.

**By (Signature):** Jill McManus

**By (Printed Signature):** Jill McManus

**By (Title):** Assistant Treasurer

**Date:** 08/26/2025